John Green, the author of several books and a longtime supporter of Partners in Health, discusses his time visiting Sierra Leone’s Lakka Government Hospital, a tuberculosis treatment center. He talks about Henry, a 16-year old boy cured from multi-drug resistant TB as the first Sierra Leonean patient to receive a newly designed treatment regimen that included bedaquiline in 2021. With J&J's patent on bedaquiline ending soon, John Green provides us with a call to action to urge J&J to relinquish its extended patent claims and make the drug more widely accessible and affordable. Read more here.
top of page
Recent Posts
See AllThe results of the TB-CHAMP trial were recently published. They showed that prophylactic levofloxacin can significantly reduce the risk...
190
This month, the Indian Patent Office denied the last of the three Janssen patent extension applications for bedaquiline. While TB...
100
The Institute of Tropical Medicine has announced two initiatives to honor the legacy of Armand Van Deun: a new meeting room in his name...
560
bottom of page
Comentários